Assess whether to resubmit, meet, or pause the program (daa929)

SITUATION A CRL citing manufacturing, not efficacy put 505(b)(2) literature-to-product bridge table in front of regulatory-affairs lead in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / Pharmacovigilance close is to resubmit, meet, or from 505(b)(2) literature-to-product bridge table, and the live options are To resubmit, meet,, Pause the program.

DECISION Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Regulatory-affairs lead can defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge. 2. Regulatory-affairs lead cannot defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table; Pause the program is what the extract actually supports after a CRL citing manufacturing, not efficacy. 3. A CRL citing manufacturing, not efficacy never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to resubmit, meet, or. 4. Two facts in 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy conflict for regulatory-affairs lead; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim regulatory-affairs lead would keep. 3. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a CRL citing manufacturing, not efficacy and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy). The follow-on Pharmacovigilance action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for regulatory-affairs lead in a rare-disease team designing a pediatric plan